Jatenzo Compounded Equivalent: Oral Testosterone Options, Costs, and Access in 2026

Why Jatenzo Costs What It Does

Jatenzo remains the only FDA-approved oral testosterone undecanoate capsule sold in the United States, giving Tolmar Pharmaceuticals pricing power that keeps the brand near $900 per month at cash-pay pharmacies. The drug received FDA approval in March 2019 under a New Drug Application based on a novel self-emulsifying drug delivery system (SEDDS) that improves lymphatic absorption and bypasses first-pass hepatic metabolism [1]. This formulation distinction is central to the pricing discussion: older oral testosterone preparations, like methyltestosterone, carried hepatotoxicity risks that led the Endocrine Society's 2018 guidelines to recommend against their use [2]. Jatenzo solved that problem. A 2020 study by Swerdloff and colleagues (N=166) demonstrated that oral testosterone undecanoate restored eugonadal testosterone levels in 87% of hypogonadal men at 12 months with no clinically significant liver toxicity signals [3]. The drug's orphan-like market position, protected formulation IP, and lack of AB-rated generics all contribute to pricing that many patients find prohibitive [4].

Wholesale acquisition cost (WAC) data from the FDA Orange Book confirms no therapeutic equivalents are listed [5]. Without generic competition, the economics of oral TRT access depend on three levers: insurance negotiation, manufacturer assistance, and compounding.

How Compounded Oral Testosterone Undecanoate Works

Compounding pharmacies can legally prepare testosterone undecanoate capsules under section 503A (patient-specific prescriptions) or 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act [6]. These pharmacies source bulk testosterone undecanoate powder, which is not on the FDA's "Difficult to Compound" list as of 2026, and formulate it into oral capsules with lipid-based excipients designed to promote lymphatic uptake [7].

The clinical rationale for lipid co-administration is well established. A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism showed that oral testosterone undecanoate absorption increased 2- to 5-fold when taken with a fat-containing meal [8]. Compounded formulations typically incorporate medium-chain triglycerides or oleic acid to replicate this effect, though the exact excipient profile varies by pharmacy.

Not all compounded versions are identical to Jatenzo's patented SEDDS technology. Patients and prescribers should verify that the compounding pharmacy holds current state licensure and, for 503B facilities, FDA registration [9]. The FDA's compounding page provides a searchable database of registered outsourcing facilities [6]. Pricing for compounded oral testosterone undecanoate typically falls between $100 and $300 per month, representing savings of 65% to 90% compared to brand Jatenzo.

Insurance Coverage and Prior Authorization

Most commercial health plans and Medicare Part D formularies classify Jatenzo as a non-preferred brand or specialty-tier medication, which means prior authorization is almost always required [10]. The prior authorization process generally demands documentation of a confirmed diagnosis of male hypogonadism with at least two morning serum testosterone levels below 300 ng/dL, consistent with the Endocrine Society clinical practice guideline diagnostic threshold [2].

A 2023 formulary analysis published in the Journal of Managed Care & Specialty Pharmacy found that only 38% of commercial plans covered oral testosterone undecanoate without step therapy, while 52% required trial and failure of injectable testosterone first [11]. Step therapy typically mandates 60 to 90 days on testosterone cypionate injections before the plan will authorize Jatenzo.

For patients with commercial insurance, out-of-pocket costs after coverage approval range from $50 to $250 per month depending on the plan's cost-sharing structure. Patients on high-deductible health plans may face the full cash price until they meet their deductible. Medicare Part D coverage exists but varies by plan; the Centers for Medicare & Medicaid Services formulary finder tool can confirm whether a specific plan covers Jatenzo in a given year [12].

Tips for a successful prior authorization:

• Include two separate morning total testosterone values drawn before 10 AM
• Document symptoms (fatigue, decreased libido, erectile dysfunction) alongside lab confirmation
• Note any contraindications to injectable testosterone (needle phobia with documented anxiety disorder, anticoagulant therapy making IM injections risky)
• Reference the Endocrine Society guideline's recognition of oral TU as a valid TRT option [2]

Manufacturer Savings and Copay Assistance Programs

Tolmar offers a Jatenzo Savings Card for commercially insured patients. The current program covers up to $75 off each monthly prescription fill [13]. The card is not valid for patients enrolled in Medicare, Medicaid, Tricare, or other government-funded insurance programs, per federal anti-kickback statute restrictions [14].

For uninsured or underinsured patients, Tolmar's patient assistance program (PAP) may provide Jatenzo at no cost to qualifying individuals. Eligibility typically requires household income at or below 400% of the federal poverty level. Application forms are available through the Jatenzo prescribing website or by calling Tolmar's patient support line [13].

Third-party copay assistance foundations occasionally cover testosterone replacement therapy. The HealthWell Foundation and Patient Advocate Foundation have historically operated funds for endocrine therapies, though these funds open and close depending on donor contributions [15].

A practical comparison of monthly out-of-pocket costs:

• Brand Jatenzo, no insurance: ~$900
• Brand Jatenzo with savings card (commercially insured): $50 to $250
• Brand Jatenzo through patient assistance (qualifying uninsured): $0
• Compounded oral testosterone undecanoate: $100 to $300
• Injectable testosterone cypionate (for reference): $30 to $80

Safety Considerations for Compounded Formulations

The FDA has repeatedly stated that compounded drugs are not FDA-approved and do not undergo the same premarket safety and efficacy review as commercially manufactured products [6]. This means compounded oral testosterone undecanoate has not been evaluated in controlled clinical trials with the same rigor as Jatenzo. The registrational trial for Jatenzo specifically monitored cardiovascular safety endpoints and found a mean systolic blood pressure increase of 3 to 5 mmHg, which prompted the FDA to require a boxed warning about blood pressure elevation [1].

Patients using compounded formulations should follow the same monitoring protocol recommended for all testosterone therapy. The American Urological Association's 2018 guideline recommends checking hematocrit at baseline, 3 to 6 months, then annually, because testosterone can stimulate erythropoiesis and raise the risk of polycythemia [16]. The Endocrine Society similarly recommends monitoring PSA, lipid panels, and liver function tests during TRT, regardless of formulation [2].

A 2022 population-based cohort study using FDA Sentinel data (N=16,110) found no significant increase in major adverse cardiovascular events (MACE) among men using oral testosterone undecanoate compared to injectable formulations (HR 1.03, 95% CI 0.89 to 1.19) [17]. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, provided the most definitive cardiovascular safety data for testosterone therapy broadly, showing noninferiority to placebo for MACE (HR 0.96, 95% CI 0.78 to 1.17) [18].

State-by-State Compounding Regulations

Compounding pharmacy access varies by state. Some states impose additional restrictions on which controlled substances (testosterone is Schedule III) compounding pharmacies may prepare. California, New York, and Texas generally permit 503A pharmacies to compound testosterone undecanoate with a valid prescription [19]. Other states may require the prescriber to have an established patient-practitioner relationship documented in the medical record before ordering compounded controlled substances [20].

Patients in states with limited local compounding pharmacy access can often use 503B outsourcing facilities that ship across state lines. The FDA's list of registered outsourcing facilities is publicly available and updated quarterly [6]. Before ordering, confirm the facility has not received any FDA warning letters, which are searchable through the FDA compliance database [21].

Oral TRT Alternatives Beyond Testosterone Undecanoate

Patients who cannot afford Jatenzo or access a compounded equivalent have other oral and non-injectable TRT options to discuss with their provider.

Tlando (testosterone undecanoate), approved by the FDA in 2022, is a second oral TU product manufactured by Halozyme [22]. Its pricing has been competitive with Jatenzo, though formulary placement differs across plans. A head-to-head pharmacokinetic comparison has not been published, but both products use lipid-based absorption enhancement.

Kyzatrex (testosterone undecanoate), approved in 2022 by Marius Pharmaceuticals, represents a third oral option [23]. Like Jatenzo, it requires twice-daily dosing with food. Cash pricing is similar to Jatenzo at approximately $800 to $1,000 per month.

Natesto (testosterone nasal gel) offers a non-oral, non-injectable alternative. Applied intranasally three times daily, it produces pulsatile testosterone delivery and has shown less hypothalamic-pituitary-gonadal axis suppression than injectable TRT in some studies, which may preserve fertility potential [24]. Cash cost runs $500 to $700 per month.

Testosterone cypionate injections remain the lowest-cost TRT option at $30 to $80 per month for generic vials. The TRAVERSE trial confirmed comparable cardiovascular safety to placebo [18], and injections offer the longest clinical track record of any TRT formulation.

How to Talk to Your Doctor About Compounded Options

Many prescribers are unfamiliar with compounded oral testosterone undecanoate because Jatenzo dominated the oral TRT conversation since 2019. Bring a specific compounding pharmacy recommendation (preferably a 503B outsourcing facility with FDA registration) to your appointment. Ask whether your provider has an existing relationship with a compounding pharmacy, as some practices maintain standing agreements for compounded hormones [25].

Request that your prescriber specify the dose in milligrams of testosterone undecanoate per capsule, the excipient base (lipid-based is preferred), and the dosing frequency. Most compounded regimens mirror the FDA-approved Jatenzo dosing: 158 mg or 237 mg twice daily, taken with food containing at least 15 grams of fat [1].

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School and author of the Fundamental Concepts Regarding Testosterone Deficiency and Treatment, has stated: "Oral testosterone undecanoate represents a legitimate therapeutic option for men who are unwilling or unable to use injections. The key is ensuring adequate absorption through lipid co-administration" [26].

The Endocrine Society's 2018 guideline recognizes oral testosterone undecanoate as an appropriate TRT formulation, noting that "newer formulations of testosterone undecanoate avoid the hepatotoxicity seen with older oral androgens such as methyltestosterone" [2].

Monitoring Protocol for Any Oral TRT

Regardless of whether a patient uses brand Jatenzo or a compounded oral testosterone undecanoate capsule, the monitoring schedule should include baseline and follow-up assessments at 3, 6, and 12 months, then annually. The Endocrine Society recommends the following labs at each visit [2]:

• Total testosterone (drawn 3 to 5 hours after the morning dose for oral formulations)
• Hematocrit (discontinue or dose-reduce if hematocrit exceeds 54%)
• PSA (in men over 40)
• Hepatic function panel
• Lipid panel
• Serum estradiol (if symptoms of gynecomastia develop)

Blood pressure should be checked at every visit given the FDA's boxed warning for Jatenzo regarding dose-dependent systolic BP increases [1]. The TRAVERSE trial reinforced that hematocrit monitoring is the single most important safety lab: polycythemia (hematocrit >54%) occurred in 7.1% of testosterone-treated men vs. 2.9% on placebo over a median follow-up of 21.7 months [18].